Menu

Top Stories

Published on Tuesday, November 6, 2018

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.

MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.

TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.

“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.

The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.

To read the full press release, please click here.

Source: Mereo BioPharma Group plc


Print

Alpha-1 Registry a database of Alphas and carriers interested in clinical trials

Wednesday, October 21, 2015
Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition that can lead to lung disease in adults and/or liver disease at any age. In Alpha-1, there is a low level of protein in the blood called alpha-1 antitrypsin, or AAT. The low level...
Divider

MASAC: Alphas should be skeptical of stem cell "therapy" claims, participate only in approved clinical trials

Thursday, October 15, 2015
The Medical and Scientific Advisory Committee (MASAC) of the Alpha-1 Foundation  has drafted a letter cautioning Alphas with lung or liver disease against unproven stem cell and other cell-based "therapies" being advertised on the Internet....
Divider

Alpha-1 and COPD foundations express support for Califf as new FDA commissioner

Thursday, October 15, 2015
The Alpha-1 Foundation and COPD Foundation today issued a statement of support for Robert Califf, MD, as the new commissioner of the U.S. Food and Drug Administration (FDA). Califf, 63, joined the FDA as deputy commissioner in March after more...
Divider

FDA seeks more comments about Alpha-1 on its website

Tuesday, October 6, 2015
The U.S. Food and Drug Administration (FDA) has asked Alphas and their supporters to post written comments about their experiences with Alpha-1 on its website. The comments will be added to those that were presented in person and online to the...
Divider

Alphas, caregivers pack FDA meeting to express their concerns and the need for new treatments

Thursday, October 1, 2015
Alphas and Alpha-1 caregivers packed a public meeting held by the U.S. Food and Drug Administration (FDA) Tuesday, Sept. 29, in Silver Spring, MD, to discuss Patient-Focused Drug Development for Alpha-1 Antitrypsin Deficiency (Alpha-1). Charlotte...
Divider

People with Alpha-1 Antitrypsin Deficiency Share Their Concerns with the FDA and Call for New Treatments

Friday, September 25, 2015
SILVER SPRING, Md., Oct. 2, 2015 /PRNewswire/ -- Some 250 people with Alpha-1 Antitrypsin Deficiency (Alpha-1), their caregivers and supporters filled the room at a public meeting held Sept. 29 by the U.S. Food and Drug Administration (FDA)...
Divider

Inhibitor slows lung decline in inherited emphysema, studies show

Wednesday, September 23, 2015
AMSTERDAM — In patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited condition that can cause emphysema, treatment with a plasma-derived alpha-1 proteinase inhibitor (A1-PI) slows the loss of lung density, according to results...
Divider

Alphas to "make their voice heard" at FDA

Monday, September 21, 2015
Jesse Young suffered from liver failure, and desperately needed a transplant. Family members were tested, but none qualified as a donor. His then-girlfriend, Rachel, insisted on taking the test herself. Reluctantly, he agreed. A couple of weeks...
Divider

Boston University joins Alpha-1 adult liver disease study

Thursday, September 10, 2015
Boston University’s medical school has joined two other well-respected research institutions in conducting a study of liver disease in adult Alphas. The goal of the groundbreaking “Alpha-1 Antitrypsin Deficiency Adult Clinical and...
Divider

Inhibrx and The Alpha-1 Project collaborate to develop genetically engineered form of augmentation therapy

Thursday, September 10, 2015
MIAMI – Inhibrx, a biologic therapeutic company that focuses on the treatment of unmet medical needs, and The Alpha-1 Project, Inc. (TAP), a wholly owned subsidiary of the Alpha-1 Foundation, are working together to develop a new...
Divider

Obama nominates FDA’s No. 2 official to lead agency

Wednesday, September 9, 2015
WASHINGTON — President Barack Obama has nominated the Food and Drug Administration’s second-highest ranking official, Robert Califf, MD, to lead the agency, which regulates consumer products ranging from medications to seafood to...
Divider

Smartphone could monitor wheezing

Monday, August 31, 2015
A simple breath can reveal a lot about someone's health. That's why researchers are developing wearable devices that keep continuous tabs on the wearer's lungs. But while gadgetry often gets the attention, it's the algorithms behind the gadgets...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.